SynthesisFrontiers in cellular and infection microbiology2026
Advances in NLRP3 inflammasome research in viral infections: evolution, trends, and future directions.
Synthesis in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: The NLRP3 inflammasome is a central innate immune sensor in virus-associated inflammation, yet the global research landscape of NLRP3 in viral infections remains unmapped. This study aimed to characterize its structure, evolution, research hotspots, and translational status. Methods: We performed a dual-database bibliometric analysis of publications from the Web of Science Core Collection (WoSCC) and Scopus through April 28, 2026, analyzing each database independently with cross-validation. Publication trends, collaboration networks, journal and co-citation patterns, citation bursts, keyword co-occurrence, and trend topics were examined using bibliometrix, VOSviewer, and CiteSpace. Results: Publications from WoSCC (n = 1,544) and Scopus (n = 1,495) were analyzed independently and cross-validated. Annual output rose steadily from 2009 to a peak in 2025, expanding most steeply during 2019-2022. China and the United States dominated publication output, and cumulative all-affiliation output suggests that China overtook the United States around 2021-2022 despite its lower international collaboration ratio. The most productive institutions, led by the Chinese Academy of Sciences, shifted toward Chinese affiliations after 2018-2020. High-volume journals such as Frontiers in Immunology sustained routine output, whereas a small number of landmark papers in Nature dominated citation influence. Three recurrent hotspots emerged: viral triggers and NLRP3 activation mechanisms, the balance between antiviral defense and hyperinflammation, and NLRP3-associated cell death with therapeutic targeting. After 2022, trend topics shifted toward therapy, NRF2 regulation, diagnosis, and brain pathology, while clinical translation remained largely preclinical. Conclusion: This study delineates the advancements in NLRP3 inflammasome research related to viral infections by systematically mapping its evolutionary trajectory, core research trends, and priority future directions. The analysis outlines the structural and collaborative landscape of the field and may inform future mechanistic investigations, cross-institutional collaborations, and clinical research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.